Abstract: Provided are a lipid and a composition that can effectively deliver an introduction compound such as a nucleic acid to a target cell, tissue, or the like in vivo.

Abstract: The present invention provides a cationic lipid which can be used for nucleic acid delivery to a cytoplasm and which is possible to solve the problem of physical stability of a lipid complex. This cationic lipid is a compound represented by the general formula (3) or a pharmaceutically acceptable salt thereof: wherein, L is an alkyl having 7-12 carbon atoms or an alkenyl having 7-12 carbon atoms, R is an alkyl having 1-2 carbon atoms, and n1 and n2 are independently an integer of 1-3.

Abstract: The present invention provides a cationic lipid which can be utilized for nucleic acid delivery into the cytoplasm. The cationic lipid of the present invention is, for example, a compound represented by the following Formula (1) or a pharmaceutically acceptable salt thereof.

Abstract: The present invention provides a cationic lipid which can be used for nucleic acid delivery to a cytoplasm and which is possible to solve the problem of physical stability of a lipid complex. This cationic lipid is a compound represented by the general formula (3) or a pharmaceutically acceptable salt thereof: wherein, L is an alkyl having 7-12 carbon atoms or an alkenyl having 7-12 carbon atoms, R is an alkyl having 1-2 carbon atoms, and n1 and n2 are independently an integer of 1-3.

Abstract: The present invention provides a cationic lipid which can be used for nucleic acid delivery to a cytoplasm and which is possible to solve the problem of physical stability of a lipid complex. This cationic lipid is a compound represented by the general formula (3) or a pharmaceutically acceptable salt thereof: wherein, L is an alkyl having 7-12 carbon atoms or an alkenyl having 7-12 carbon atoms, R is an alkyl having 1-2 carbon atoms, and n1 and n2 are independently an integer of 1-3.

Abstract: The present invention provides a cationic lipid which can be utilized for nucleic acid delivery into the cytoplasm. The cationic lipid of the present invention is, for example, a compound represented by the following Formula (1) or a pharmaceutically acceptable salt thereof.

Abstract: An anti-aging preparation for cutaneous application which prevents cutaneous aging, a collagen cross-linking inhibitory preparation for cutaneous application which inhibits collagen cross-linking occurring predominantly in the dermis to maintain skin elasticity and to prevent wrinkles or sagging, and an anti-UV preparation for cutaneous application which protects the skin from harmful effects caused by excessive exposure to ultraviolet rays of sunlight are disclosed. The preparation contains one or two aminoethyl compounds represented by formula (I):NH.sub.2 CH.sub.2 CH.sub.2 X (I)wherein X represents --SO.sub.2 H or --SO.sub.2 SH, and preferably contains at least one ultraviolet protective agent.

Abstract: An anti-aging preparation for cutaneous application which prevents cutaneous aging, a collagen cross-linking inhibitory preparation for cutaneous application which inhibits collagen cross-linking occurring predominantly in the dermis to maintain skin elasticity and to prevent wrinkles or sagging, and an anti-UV preparation for cutaneous application which protects the skin from harmful effects caused by of excessive exposure to ultraviolet rays of sunlight are disclosed. The preparation contains one or two aminoethyl compounds represented by formula (I):NH.sub.2 CH.sub.2 CH.sub.2 X (I)wherein X represents --SO.sub.2 H or --SO.sub.2 SH, and preferably contains at least one ultraviolet protective agent.

Abstract: A method for preparing 2,2-disubstituted thiazolidine involves reacting aminoalkyl hydrogen-sulfate with a compound having hydrosulfide ion in the presence of ketone. According to the present method, such thiazolidine can be prepared in good yield and desired purity without using harmful ethylenimine as a starting material.

Abstract: A process for preparing a cysteamine-S-substituted compound involves reacting ethyleneimine or ethyleneimine derivatives with a thiosulfate or thiophosphate in the presence of a cation exchanger of a free type. Use of the cation exchanger of a free type in this reaction allows preparation of the cysteamine-S-substituted compound with an amazingly high purity in a high yield.